Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035057) COMPOSITIONS AND METHODS FOR TREATING EWING FAMILY TUMORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/035057 International Application No.: PCT/US2016/047984
Publication Date: 02.03.2017 International Filing Date: 22.08.2016
IPC:
A61K 31/385 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
38
having sulfur as a ring hetero atom
385
having two or more sulfur atoms in the same ring
Applicants:
THE METHODIST HOSPITAL [US/US]; 6565 Fannin MS D-200 Houston, Texas 77030, US
Inventors:
ZHAO, Hong; US
WONG, Stephen T.C.; US
Agent:
WIDOM, Russell L.; US
Priority Data:
62/209,19724.08.2015US
62/209,64525.08.2015US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING EWING FAMILY TUMORS
(FR) COMPOSITIONS ET MÉTHODES DESTINÉES AU TRAITEMENT DE TUMEURS DE LA FAMILLE EWING
Abstract:
(EN) A method for treating a sarcoma by administering a tyrosine kinase inhibitor and a biguanide compound. Also described is a method for treating a tumor of the Ewing Sarcoma family by obtaining a tumor sample; determining in the sample gene expression levels of ACTB, B2M, MLH1, PRKDC, XPC, APEX1, ERCC5, MMS19, or RAD23; and administering a tyrosine kinase inhibitor and a biguanide compound. Furthermore, a pharmaceutical composition for treating a Ewing family tumor is disclosed. The composition contains a tyrosine kinase inhibitor, a biguanide compound, and a pharmaceutically acceptable excipient.
(FR) L'invention concerne une méthode de traitement de sarcomes par administration d'un inhibiteur de la tyrosine kinase et d'un composé biguanide. L'invention concerne également une méthode de traitement de tumeurs de la famille des sarcomes d'Ewing, en réalisant les étapes consistant à obtenir un échantillon tumoral ; à déterminer dans l'échantillon les niveaux d'expression génique de ACTB, B2M, MLH1, PRKDC, XPC, APEX1, ERCC5, MMS19 ou RAD23 ; et à administrer un inhibiteur de la tyrosine kinase et un composé biguanide. En outre, l'invention concerne une composition pharmaceutique destiné au traitement de tumeurs de la famille Ewing. La composition contient un inhibiteur de tyrosine kinase, un composé biguanide, et un excipient pharmaceutiquement acceptable.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)